Comparative Pharmacology
Head-to-head clinical analysis: CEFUROXIME SODIUM IN PLASTIC CONTAINER versus SPECTRACEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFUROXIME SODIUM IN PLASTIC CONTAINER versus SPECTRACEF.
CEFUROXIME SODIUM IN PLASTIC CONTAINER vs SPECTRACEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime is a beta-lactam cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has bactericidal activity against susceptible organisms.
Cefditoren, a third-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
1.5 g IV every 8 hours for moderate to severe infections; may be increased to 3 g IV every 8 hours for severe or life-threatening infections.
400 mg orally twice daily for 10-14 days.
None Documented
None Documented
Terminal elimination half-life: 1.2-1.9 hours. Prolonged in renal impairment (up to 15-20 hours with CrCl <20 mL/min).
Terminal elimination half-life: 2.5 hours (range 2.0-3.0 hours) in healthy adults; prolonged in renal impairment (up to 10 hours in severe impairment)
Renal excretion: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary/fecal: <10%.
Renal: 88% as unchanged drug, Fecal: negligible, Biliary: minimal
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic